ACXP · Acurx Pharmaceuticals, Inc. · Executive Compensation
$1.42
-0.01 (-0.66%)
At close · Sep 9
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 13, 2026
Market Cap
$7.48M
Shares
5.27M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Robert DeLuccia | Executive Chairman | $1,463,430 |
| David P. Luci | President and Chief Executive Officer | $1,431,383 |
| Robert Shawah | Chief Financial Officer | $907,463 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Robert DeLuccia | Executive Chairman | $1,056,436 |
| David P. Luci | President and Chief Executive Officer | $1,023,878 |
| Robert Shawah | Chief Financial Officer | $675,038 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Robert DeLuccia | Executive Chairman | $677,186 |
| David P. Luci | President and Chief Executive Officer | $655,000 |
| Robert Shawah | Chief Financial Officer | $375,000 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Robert DeLuccia | Executive Chairman | $4,509,094 |
| David P. Luci | President and Chief Executive Officer | $4,487,465 |
| Robert Shawah | Chief Financial Officer | $1,462,738 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert DeLuccia | Executive Chairman | $617,570 |
| David P. Luci | President and Chief Executive Officer, Director | $596,037 |
| Robert Shawah | Chief Financial Officer | $152,500 |
Key facts
CIK
1736243
CUSIP
00510M203
13F (30d)
13 filings
13 filers
Visit website
Investor relations